HomeInsightsStock Comparison

Glenmark Pharmaceuticals Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Glenmark Pharmaceuticals Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Last Updated on: Dec 20, 2025

Key Highlights

  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 1990 as of 19 Dec 15:30.
  • The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 41.5 on March 2025 . This represents a CAGR of 32.99% over 6 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 22.5 on March 2020 to 38.1 on March 2025 . This represents a CAGR of 9.18% over 6 years.
  • The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 43458 crore on March 2025 . This represents a CAGR of 39.83% over 6 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 84504 crore on March 2020 to ₹ 416392 crore on March 2025 . This represents a CAGR of 30.45% over 6 years.
  • The revenue of Glenmark Pharmaceuticals Ltd for the Sep '25 is ₹ 6247 crore as compare to the Jun '25 revenue of ₹ 3290 crore. This represent the growth of 89.84% The revenue of Sun Pharmaceutical Industries Ltd for the Sep '25 is ₹ 14948 crore as compare to the Jun '25 revenue of ₹ 14315 crore. This represent the growth of 4.42%.
  • The ebitda of Glenmark Pharmaceuticals Ltd for the Sep '25 is ₹ 1175 crore as compare to the Jun '25 ebitda of ₹ 283.73 crore. This represent the growth of 314.15% The ebitda of Sun Pharmaceutical Industries Ltd for the Sep '25 is ₹ 4996 crore as compare to the Jun '25 ebitda of ₹ 3948 crore. This represent the growth of 26.57%.
  • The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 610.43 crore over 10 quarters. This represents a CAGR of 65.54% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2013 crore to ₹ 3137 crore over 10 quarters. This represents a CAGR of 19.42% .
  • The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 4.38 % on March 2025 . This represents a CAGR of -2.85% over 6 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 29.89 % on March 2020 to 89.64 % on March 2025 . This represents a CAGR of 20.09% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

About Sun Pharmaceutical Industries Ltd

  • Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
  • The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
  • It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
  • The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals Ltd soars 0.2%, gains for fifth straight session

Glenmark Pharmaceuticals Ltd is up for a fifth straight session today. The stock is quotin...

Read more

15 Dec 2025 13:00

News

Glenmark USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Leucovorin ...

Read more

11 Dec 2025 09:08

News

Glenmark Pharma's U.S. arm to launch Leucovorin Calcium Injection in the U.S. Market

The product is bioequivalent and therapeutically equivalent to the reference listed drug (...

Read more

11 Dec 2025 11:55

News

Glenmark's Aurangabad unit completes USFDA inspection

Glenmark Pharmaceuticals announced that the U.S. Food and Drug Administration (U.S. FDA) c...

Read more

01 Dec 2025 09:14

News

Glenmark Pharma's Chhatrapati Sambhajinagar facility clears USFDA inspection with zero observations

According to the company's exchange filing, the inspection was conducted between 24 Novemb...

Read more

01 Dec 2025 10:37

News

Glenmark's Monroe facility concludes USFDA inspection

Glenmark Pharmaceuticals has received Establishment Inspection Report (EIR) with a Volunta...

Read more

27 Nov 2025 10:43

Sun Pharmaceutical Industries Ltd News Hub

News

USFDA classifies Sun Pharma's Baska facility inspection as Official Action Indicated

Sun Pharmaceutical Industries announced that the US FDA conducted an inspection at the Com...

Read more

18 Dec 2025 09:19

News

Sun Pharma declines after US FDA classifies Baska facility inspection as OAI

The American drug regulator had inspected the company's facility from 8 September 2025 to ...

Read more

18 Dec 2025 11:55

News

Sun Pharma launches innovative drug ILUMYA (Tildrakizumab) in India

Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (...

Read more

01 Dec 2025 13:19

News

Sun Pharmaceutical Industries Ltd up for fifth session

Sun Pharmaceutical Industries Ltd is up for a fifth straight session in a row. The stock i...

Read more

13 Nov 2025 13:00

News

Sun Pharma records PAT of Rs 3,118 crore in Q3

Formulation sales in India were Rs 4,734.8 crore, registering a growth of 11%. India Formu...

Read more

06 Nov 2025 11:18

News

Sun Pharmaceutical Industries Ltd up for third consecutive session

Sun Pharmaceutical Industries Ltd is up for a third straight session today. The stock is q...

Read more

17 Oct 2025 13:05

SWOT Analysis Of Sun Pharmaceutical Industries Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Sun Pharmaceutical Industries Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 56,179 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 418,707 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd?

As of December 20, 2025, the Glenmark Pharmaceuticals Ltd stock price is INR ₹1990.75. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1745.1.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions